Upon completion of the video presentation, to finish the activity and claim your credit, please click
here.
This activity has expired, credit is no longer available.
This activity is supported by an educational grant from Genentech.
Nuances in the Management of Aggressive Lymphomas
Paul A. Hamlin, MD
Memorial Sloan Kettering Cancer Center
Michelle Wisniewski, PA
Memorial Sloan Kettering Cancer Center
Treatment for both Hodgkin and non-Hodgkin’s lymphoma now includes chemotherapy, targeted therapy, and new immunotherapies. As research continues to shine the light on tumor genetics, clinical variability, and new treatment approaches, advanced practitioners (APs) need to translate this information to the bedside in the management of aggressive lymphomas. This educational activity will provide APs with the latest update on emerging treatments for aggressive, relapsed/refractory lymphomas, as well as potential adverse events and how to manage them, with the goal of optimizing treatment effectiveness and patient outcomes.
These CME/CE/CPE accredited activities are jointly provided by
